HITE Hedge Asset Management LLC Sells 95,957 Shares of Ralliant Corporation $RAL

HITE Hedge Asset Management LLC cut its stake in shares of Ralliant Corporation (NYSE:RAL) by 40.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 141,390 shares of the company’s stock after selling 95,957 shares during the period. HITE Hedge Asset Management LLC’s holdings in Ralliant were worth $7,198,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Danske Bank A S bought a new position in shares of Ralliant during the fourth quarter valued at $25,000. Allworth Financial LP increased its holdings in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. V Square Quantitative Management LLC bought a new position in shares of Ralliant during the fourth quarter valued at $26,000. Palisade Asset Management LLC bought a new stake in Ralliant in the 3rd quarter worth about $26,000. Finally, Rothschild Investment LLC increased its holdings in Ralliant by 98.1% in the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after buying an additional 303 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently commented on RAL shares. Oppenheimer lifted their price objective on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. Royal Bank Of Canada lifted their price objective on Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Finally, Barclays lifted their price objective on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ralliant currently has an average rating of “Moderate Buy” and a consensus target price of $67.30.

Ralliant Price Performance

NYSE RAL opened at $66.00 on Friday. Ralliant Corporation has a one year low of $37.27 and a one year high of $67.01. The stock has a 50-day moving average of $53.04 and a 200 day moving average of $49.83. The company has a market capitalization of $7.39 billion and a price-to-earnings ratio of -6.03. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million during the quarter. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts forecast that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is currently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.